http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017029498-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b0c198757da18cf77dfbdcef00abb70 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2016-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_633be6ba2d3a0b55a6ea5f830795693d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f442daa2656240cc2ab799f4f6c555ab |
| publicationDate | 2017-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2017029498-A1 |
| titleOfInvention | 2-sulfonylpyrimidines |
| abstract | The invention relates to 2-sulfonylpyrimidine compounds and salts and solvates thereof for use in the treatment of a proliferative disease such as cancers. The 2- sulfonyl-primidine compounds may be administered, either simultaneously or sequentially, with one or more pharmacologically active compounds and salts and solvates thereof such as an inhibitor of glutamate cysteine ligase. The 2- sulfonylpyrimidine compound may be represented by formula (I): (I) wherein: R 1 is selected from C 1-6 alkyl, C 6-12 aryl, C 7-18 aralkyl, 6- to 15-membered heteroaralkyl and 6- to 12-membered heterocyclylalkyl wherein each of these groups are optionally substituted with from one to three optional substituents; R 2 is selected from CF 3 , O-C(O)-R 6 , C(O)R 7 , C(O)NHR 7 and NHC(O)R 7 ; R 3 is selected from H, F, CI, Br, I, OH, C 1-6 alkyl, OC 1-6 alkyl, CH 2 F, CHF 2 , CF 3, CN, NO 2 , CO 2 R 8 , C(O)NHR 10 , NHC(O)R 10 , (CH 2 ) z -NR 8 R 9 and (CH 2 ) z -NH-C(=NH)-NH 2 ; R 4 is selected from H, C 1-6 alkyl and CH 2 R 11 ; R 5 is selected from C 1-6 alkyl; R 6 is selected from H and C 1-6 alkyl; R 7 is selected from 5 to 9-membered heteroaryl groups, and phenyl wherein these groups are optionally substituted with from one to three optional substituents; and wherein the heteroaryl group is attached to the rest of compound of formula (I) by a carbon ring atom; R 8 and R 9 are independently selected from H, C 1-6 alkyl and benzyl; R 10 is selected from 5- to 9-membered heteroaryl groups, 5- and 6-membered heterocyclyl, and phenyl wherein these groups are optionally substituted with from one to three optional substituents; R 11 is phenyl optionally substituted; and z is selected from an integer selected from o to 6. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019173806-A1 |
| priorityDate | 2015-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 622.